A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 22, Issue 3, 1997, Pages 193-199

  Jones, H K ^a   Kelly, H C ^a   Hutchison, M ^a   Yates, R A ^a   Ross, F ^b   Lomax, C ^b   Freestone, S ^b   Webb, D ^b  

^a ASTRAZENECA   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carbapenem; Injection; Meropenem; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; BILIRUBIN; MEROPENEM;

ADULT; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; FINGER FRACTURE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; NAUSEA; NECK PAIN; NORMAL HUMAN; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; RASH; VOLUNTEER;

EID: 0030712259     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189806     Document Type: Article

References (23)

1. Fukasawa M., Sumita, Y., Harabe E.T., Tanio T., Nouda H., Kohzuki T. (1992) : Stability of meropenem and the effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase-I. Antimicrob. Agents Chemother., 36, 1577-1579.
2. Wiseman L.R., Wagstaff A.J., Brogden R.N., Bryson H.M. (1995) : Meropenem. A Review of its antibacterial activity, Pharmacokinet Prop Clin Efficacy Drugs, 50, 73-101.
3. Edwards J.R. (1995) : A microbiological overview. J. Antimicrob. Chemother., 6 Suppl A, 1-17.
4. Bax R.P., Bastain W., Featherstone A., Wilkinson D.M., Hutchison M., Haworth S.J. (1989) : The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother., 24 Suppl. A, 311-320.
5. Burman L.A., Nilsson-Ehle I., Hutchison M., Haworth S.J., Norrby S.R. (1991) : Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother., 27, 219-224.
6. Christensson B.A., Nilsson-Ehle I., Hutchison M., Haworth S.J., Öqvist B., Norrby S.R. (1992) : Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob. Agents Chemother., 36, 1532-1537.
7. Leroy A., Fillastre J.P., Borsa-Lebas F., Étienne I., Humbert G. (1992) : Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and patients with renal impairment. Antimicrob. Agents Chemother., 36, 2794-2798.
8. Kelly H.C., Hutchison M., Haworth S.J. (1995) : A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J. Antimicrob. Chemother., 36 Suppl. A, 35-41.
9. Harrison M.P., Moss S.R., Featherstone A., Fowkes A.G., Sanders A.M., Case D.E. (1989) : The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother., 24 Suppl. A, 265-277.
10. Norrby S.R., Newell P.A., Faulkner K.L., Lesky W. (1995) : Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother., 36 Suppl. A, 207-223.
11. Huizinga W.K.J., Warren B.L., Baker L.W. et al. (1995) : Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J. Antimicrob. Chemother., 36 Suppl. A, 179-189.
12. Schuler D. and the Meropenem Paediatric Study Group (1995) : Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. J. Antimicrob. Chemother., 36 Suppl. A, 99-108.
13. Klugman K.P., Friedland I.R., Bradley J.S. (1995) : Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob. Agents Chemother., 39, 1988-1992.
14. Bryne S., Maddison J., Connor P. et al. (1995) : Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J. Antimicrob. Chemother. 36, Suppl. A, 135-143.
15. Allen G.D. (1990) : MODFIT. A pharmacokinetics computer program. Biopharm. Drug Dispos., 11, 477-498.
16. Norrby S.R., Vandercam B., Louie T. et al. (1987) : Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomised multi-clinic study. Scand. J. Infect. Dis. Suppl., 52, 65-78.
17. Wang C., Calandra G.B., Aziz M.A., Brown K.R. (1985) : Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev. Infect. Dis., 7 Suppl. 3, S528-S536.
18. Gibson J.G., Evans W.A. (1937) : Clinical studies of the blood volume. Clinical application of a method employing the azo dye 'Evans blue' and the spectrophotometer. J. Clin. Invest., 16, 301-316.
19. Chiou W.L. (1979) : Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J. Pharmacokinet. Biopharm., 7, 572-536.
20. Hinderling P.H., Garrett E.R. (1976) : Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J. Pharmacokinet. Biopharm., 4, 199-230.
21. Major E., Aun C., Yate P.M. et al. (1983) : Influence of sample site on blood concentrations of ICI 35868 Br. J. Anaesth., 55, 371-375.
22. Adam H.K., Briggs L.P., Bahar M., Douglas E.J., Dundee J.W (1983) : Pharmacokinetic evaluation of ICI 35868 in man. Br. J. Anaesth., 55, 97-103.
23. Kaplin S.A., Jack M.L., Alexander K., Weinfield R.E. (1973) : Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J. Pharm. Sci., 62, 1789-1796.